Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer

This study is testing an immunotherapy drug called ivonescimab — which blocks both PD-1 (immune checkpoint) and VEGF (blood vessel growth) — for people with previously treated advanced colorectal cancer. It targets two pathways at once, which may help the immune system fight colorectal cancer more effectively than single-target drugs. **You may be eligible if...** - You are 18 or older - You have been diagnosed with advanced or metastatic colorectal cancer (adenocarcinoma) - Your cancer has known MSI or MMR status (either MSI-H or MSS) - You have already received prior treatments that have stopped working - You have at least one measurable tumor on imaging - Your organ function is adequate **You may NOT be eligible if...** - You have untreated brain metastases - You have active autoimmune disease - You have had certain recent surgeries or significant bleeding - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.